Characteristics of treated patients
| Characteristics . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age, y | 42 | 31 |
| Indication for transplantation | Treatment-related AML (cytogenetics not done) | Chemo-refractory Hodgkin disease (mixed cellularity) |
| Status of disease at transplantation | CR (last cycle of chemotherapy completed 3 months before transplantation) | Progressive and widely disseminated (involving spleen and bone marrow) |
| Prior therapy | EPOCH, 4 cycles | 6 cycles EPOCH; mantle irradiation*; thalidomide and interferon† |
| Time from HIV diagnosis to transplantation | 6 years | 5 years |
| Prior HIV-associated illnesses | NHL 3 years before transplantation; S/P 6 cycles EPOCH with CR | None |
| HAART at time of transplantation | Indinavir, stavudine, lamivudine | Nelfinavir, abacavir, lamivudine |
| CD4 (cells per μL) | 200 | 81 |
| Viral load (copies per mL) | 494 | Undetectable |
| Graft | ||
| CD34+ (× 106cells/kg) | 16.99 | 16.99 |
| CD3+ (× 108cells/kg) | 3.96 | 3.80 |
| Transduced graft | ||
| TdRev (total cells) | 4.04 × 108 | na |
| GP91 (total cells) | 2.58 × 108 | na |
| Characteristics . | Patient 1 . | Patient 2 . |
|---|---|---|
| Age, y | 42 | 31 |
| Indication for transplantation | Treatment-related AML (cytogenetics not done) | Chemo-refractory Hodgkin disease (mixed cellularity) |
| Status of disease at transplantation | CR (last cycle of chemotherapy completed 3 months before transplantation) | Progressive and widely disseminated (involving spleen and bone marrow) |
| Prior therapy | EPOCH, 4 cycles | 6 cycles EPOCH; mantle irradiation*; thalidomide and interferon† |
| Time from HIV diagnosis to transplantation | 6 years | 5 years |
| Prior HIV-associated illnesses | NHL 3 years before transplantation; S/P 6 cycles EPOCH with CR | None |
| HAART at time of transplantation | Indinavir, stavudine, lamivudine | Nelfinavir, abacavir, lamivudine |
| CD4 (cells per μL) | 200 | 81 |
| Viral load (copies per mL) | 494 | Undetectable |
| Graft | ||
| CD34+ (× 106cells/kg) | 16.99 | 16.99 |
| CD3+ (× 108cells/kg) | 3.96 | 3.80 |
| Transduced graft | ||
| TdRev (total cells) | 4.04 × 108 | na |
| GP91 (total cells) | 2.58 × 108 | na |
AML indicates acute myelogenous leukemia; CR, complete remission; NHL, non-Hodgkin lymphoma; EPOCH, etoposide, vincristine, prednisone, doxorubicin, cyclophosphamide; S/P, status post; na, not applicable.
Patient did not receive planned dose owing to disease progression.
Patient completed 1 cycle only.